Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian R Murphy

Showing results (51-60 of 122) with videos related to

Pageof 13
Sort By:
Nature|April 2, 2004
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in miceZhi-Yong Yang, Wing-Pui Kong, Yue Huang, et al.
Virology Journal|March 3, 2007
Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1Joseph E Blaney, Neeraj S Sathe, Christopher T Hanson, et al.
Vaccine|December 20, 2011
Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young childrenRuth A Karron, Bhagvanji Thumar, Elizabeth Schappell, et al.
Vaccine|June 21, 2005
Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxovirusesSheila M Nolan, Sonja R Surman, Emerito Amaro-Carambot, et al.
Vaccine|December 21, 2005
Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidatesEmmalene J Bartlett, Emerito Amaro-Carambot, Sonja R Surman, et al.
The Pediatric Infectious Disease Journal|August 11, 2011
The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young childrenRuth A Karron, Roberta Casey, Bhagvanji Thumar, et al.
Current Medical Research and Opinion|December 16, 2014
Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarinBeth L Nordstrom, Michael A Evans, Brian R Murphy, et al.
Vaccine|August 4, 2009
Codon stabilization analysis of the "248" temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidatesCindy Luongo, Lijuan Yang, Christine C Winter, et al.
Virology|November 1, 2003
Genetic diversity between human metapneumovirus subgroupsStéphane Biacchesi, Mario H Skiadopoulos, Guy Boivin, et al.
Nature Medicine|July 13, 2004
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirusElisabetta Traggiai, Stephan Becker, Kanta Subbarao, et al.
Pageof 13

Showing results (51-60 of 122) with videos related to

Sort By:
Pageof 13
Nature|April 2, 2004
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in miceZhi-Yong Yang, Wing-Pui Kong, Yue Huang, et al.
Virology Journal|March 3, 2007
Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1Joseph E Blaney, Neeraj S Sathe, Christopher T Hanson, et al.
Vaccine|December 20, 2011
Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young childrenRuth A Karron, Bhagvanji Thumar, Elizabeth Schappell, et al.
Vaccine|June 21, 2005
Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxovirusesSheila M Nolan, Sonja R Surman, Emerito Amaro-Carambot, et al.
Vaccine|December 21, 2005
Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidatesEmmalene J Bartlett, Emerito Amaro-Carambot, Sonja R Surman, et al.
The Pediatric Infectious Disease Journal|August 11, 2011
The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young childrenRuth A Karron, Roberta Casey, Bhagvanji Thumar, et al.
Current Medical Research and Opinion|December 16, 2014
Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarinBeth L Nordstrom, Michael A Evans, Brian R Murphy, et al.
Vaccine|August 4, 2009
Codon stabilization analysis of the "248" temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidatesCindy Luongo, Lijuan Yang, Christine C Winter, et al.
Virology|November 1, 2003
Genetic diversity between human metapneumovirus subgroupsStéphane Biacchesi, Mario H Skiadopoulos, Guy Boivin, et al.
Nature Medicine|July 13, 2004
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirusElisabetta Traggiai, Stephan Becker, Kanta Subbarao, et al.
Pageof 13